Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products.
It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.
The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 30, 24 | 6.39 Increased by +18.77% | 6.43 Decreased by -0.62% |
| Jul 31, 24 | 5.85 Increased by +11.64% | 6.40 Decreased by -8.59% |
| May 1, 24 | 6.17 Increased by +26.95% | 5.65 Increased by +9.20% |
| Feb 21, 24 | 4.36 Increased by +63.30% | 4.19 Increased by +4.06% |
| Nov 1, 23 | 5.38 Increased by +9.57% | 5.04 Increased by +6.75% |
| Aug 2, 23 | 5.24 Increased by +117.43% | 4.51 Increased by +16.19% |
| May 3, 23 | 4.86 Decreased by -3.38% | 4.52 Increased by +7.52% |
| Feb 22, 23 | 2.67 Increased by +13.62% | 4.51 Decreased by -40.80% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 748.90 M Increased by +22.89% | 309.10 M Increased by +15.51% | Increased by +41.27% Decreased by -6.01% |
| Jun 30, 24 | 714.90 M Increased by +19.85% | 278.10 M Increased by +7.29% | Increased by +38.90% Decreased by -10.48% |
| Mar 31, 24 | 677.70 M Increased by +33.70% | 306.60 M Increased by +27.27% | Increased by +45.24% Decreased by -4.80% |
| Dec 31, 23 | 614.70 M Increased by +25.07% | 217.10 M Increased by +64.35% | Increased by +35.32% Increased by +31.41% |
| Sep 30, 23 | 609.40 M Increased by +18.10% | 267.60 M Increased by +11.83% | Increased by +43.91% Decreased by -5.31% |
| Jun 30, 23 | 596.50 M Increased by +27.76% | 259.20 M Increased by +123.45% | Increased by +43.45% Increased by +74.90% |
| Mar 31, 23 | 506.90 M Increased by +9.74% | 240.90 M Increased by +0.42% | Increased by +47.52% Decreased by -8.50% |
| Dec 31, 22 | 491.50 M Increased by +18.38% | 132.10 M Increased by +17.74% | Increased by +26.88% Decreased by -0.54% |